- Conditions
- Headache, Migraine
- Interventions
- Ubrogepant 50 MG [Ubrelvy], Ubrogepant 100 MG [Ubrelvy]
- Drug
- Lead sponsor
- Chicago Headache Center & Research Institute
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 164 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 2
- States / cities
- Chicago, Illinois • Naperville, Illinois
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–2
of 2
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Chronic Migraine, Headache
- Interventions
- Combination of Botox + CGRPmAb (Fremanezumab 225mg/1.5mL)
- Drug
- Lead sponsor
- Chicago Headache Center & Research Institute
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Chicago, Illinois